Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$4.0 million.

  • Verrica Pharmaceuticals' Cash from Financing Activities fell 90352.64% to -$4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 167855.07%. This contributed to the annual value of $37.7 million for FY2024, which is 4916.25% down from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' Cash from Financing Activities stood at -$4.0 million, which was down 90352.64% from -$4.2 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Cash from Financing Activities high stood at $44.0 million for Q3 2023, and its period low was -$16.9 million during Q3 2022.
  • Its 5-year average for Cash from Financing Activities is $6.5 million, with a median of -$22500.0 in 2022.
  • In the last 5 years, Verrica Pharmaceuticals' Cash from Financing Activities tumbled by 3928837.21% in 2022 and then surged by 16832222.22% in 2023.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' Cash from Financing Activities stood at -$3000.0 in 2021, then crashed by 561600.0% to -$16.9 million in 2022, then soared by 99.84% to -$27000.0 in 2023, then surged by 146122.22% to $39.4 million in 2024, then plummeted by 110.11% to -$4.0 million in 2025.
  • Its Cash from Financing Activities was -$4.0 million in Q3 2025, compared to -$4.2 million in Q2 2025 and -$4.1 million in Q1 2025.